Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of Therapeutic BCI for Treatment-Resistant Depression
Summary
Motif Neurotech announced that the FDA has approved an Investigational Device Exemption (IDE) for the RESONATE Early Feasibility Study. The trial will evaluate the Motif XCS System, a small wirelessly powered implant that delivers gentle electrical stimulation to a brain region clinically shown to reduce depression symptoms. The study will be conducted at up to eight leading medical institutions including Baylor College of Medicine and Massachusetts General Brigham.
Why it matters
This marks the first FDA-approved clinical trial of an implantable therapeutic BCI specifically designed for a psychiatric indication. Treatment-resistant depression affects nearly 3 million Americans who have not found relief from two or more medications. The DOT implant, the size of a blueberry, can be delivered in a 20-minute outpatient procedure without exposing or contacting the brain, potentially offering a new treatment paradigm for mental health conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial